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Background: Correct detection of bone metastases in patients with esophageal squamous cell carcinoma is pivotal
for prognosis and selection of an appropriate treatment regimen. Whole-body bone scan for staging is not
routinely recommended in patients with esophageal squamous cell carcinoma. The aim of this study was to
investigate the role of bone scan in detecting bone metastases in patients with esophageal squamous cell
carcinoma.
Methods: We retrospectively evaluated the radiographic and scintigraphic images of 360 esophageal squamous
cell carcinoma patients between 1999 and 2008. Of these 360 patients, 288 patients received bone scan during
pretreatment staging, and sensitivity, specificity, positive predictive value, and negative predictive value of bone
scan were determined. Of these 360 patients, surgery was performed in 161 patients including 119 patients with
preoperative bone scan and 42 patients without preoperative bone scan. Among these 161 patients receiving
surgery, 133 patients had stages II + III disease, including 99 patients with preoperative bone scan and 34 patients
without preoperative bone scan. Bone recurrence-free survival and overall survival were compared in all 161
patients and 133 stages II + III patients, respectively.
Results: The diagnostic performance for bone metastasis was as follows: sensitivity, 80%; specificity, 90.1%; positive
predictive value, 43.5%; and negative predictive value, 97.9%. In all 161 patients receiving surgery, absence of
preoperative bone scan was significantly associated with inferior bone recurrence-free survival (P = 0.009,
univariately). In multivariate comparison, absence of preoperative bone scan (P = 0.012, odds ratio: 5.053)
represented the independent adverse prognosticator for bone recurrence-free survival. In 133 stages II + III patients
receiving surgery, absence of preoperative bone scan was significantly associated with inferior bone recurrence-free
survival (P = 0.003, univariately) and overall survival (P = 0.037, univariately). In multivariate comparison, absence of
preoperative bone scan was independently associated with inferior bone recurrence-free survival (P = 0.009, odds
ratio: 5.832) and overall survival (P = 0.029, odds ratio: 1.603).
Conclusions: Absence of preoperative bone scan was significantly associated with inferior bone recurrence-free
survival, suggesting that whole-body bone scan should be performed before esophagectomy in patients with
esophageal squamous cell carcinoma, especially in patients with advanced stages.
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Esophageal cancer occurs worldwide. Esophageal cancer
is the sixth most common cause of cancer death among
men in Asian countries. Adenocarcinoma and squamous
cell carcinoma are the major two histologic types of
esophageal cancer. Although adenocarcinomas are more
prevalent in the United States, [1] ninety percent of all
esophageal cancers among Asian men are esophageal
squamous cell carcinoma [1]. Despite advances in the
diagnosis and treatment of esophageal cancer in recent
decades, the prognosis of patients with esophageal squa-
mous cell carcinoma still remains poor [2]. The 5-year
survival of patients diagnosed with esophageal squamous
cell carcinoma is around 30% [3]. Despite preoperative
staging with contrast enhanced computed tomography
and endoscopic ultrasonography, [4,5] patients continue
to develop distant recurrences after esophagectomy [5-8].
The pattern of distant recurrence after esophagectomy
has previously been described [6,7]. Bhansali et al.[7]
reported that 19 (21%) of 95 patients with esophageal
squamous cell carcinoma developed distant recurrence
after esophagectomy, including 9 in the lung, 4 in the
bone, 3 in the liver, 2 in the skin, and 1 in the brain. Lamb
et al. [6] described that 28 (13.9%) of 201 patients devel-
oped distant recurrence after esophagectomy, predomin-
antly isolated hepatic (11 patients) and bone (11 patients)
metastases.
The role of whole-body bone scan has been elucidated
in several cancers including breast cancer, [9] non-small
cell lung cancer, [10] and prostate cancer [11]. However,
the role of bone scan in patients with esophageal cancer
remains controversial. Allum et al. [4] did not recom-
mend bone scan as initial staging examination in current
protocols. Quint et al. [12] suggested that routine pre-
operative bone scan identifies metastases only in the
presence of widespread metastatic or unresectable locor-
egional disease within the abdomen and thorax. Never-
theless, Jennings et al. [13] reported that skeletal system
is frequently the first site of identifiable distant meta-
static spread, and bone scan is recommended to exclude
metastatic diseases before radical treatment of esopha-
geal cancer. Most importantly, the majority of esopha-
geal cancers in previous studies evaluating the role of
bone scan [4,12,13] are esophageal adenocarcinoma, not
esophageal squamous cell carcinoma. Gockel et al. [14]
reported that these two histologic tumor types in
esophageal cancer exhibit different behavior, and squa-
mous cell carcinoma shows an earlier lymphatic spread
and a worse prognosis compared to adenocarcinoma. To
the best of our knowledge, a large series study evaluating
the role of bone scan in esophageal squamous cell car-
cinoma is lacking. Correct detection of bone metastases
in patients with esophageal squamous cell carcinoma is
crucial for prognosis and selection of an appropriatetreatment regimen. The aim of the present study was to
evaluate the role of whole-body bone scan in patients
with esophageal squamous cell carcinoma.
Methods
Patient selection
Between December 1999 and January 2008, 360 consecu-
tive patients with biopsy- proven esophageal squamous
cell carcinoma at Kaohsiung Chang Gung Memorial
Hospital were retrospectively reviewed after excluding
patients with synchronous or antecedent cancers other
than esophageal squamous cell carcinoma. This study
was approved by the Institutional Review Board of Chang
Gung Memorial Hospital. The median age of these
patients was 55 years (range 29–81 years). There were
351 men and 9 women. The median durations of follow-
up were 1886 days (range 841–3600 days) for the 61 sur-
vivors and 395 days (range 24–3600 days) for all 360
patients. Upper gastrointestinal endoscopy was per-
formed to establish the diagnosis, appearance, extent and
level of the tumor. After the diagnosis of esophageal
squamous cell carcinoma, spiral computed tomography
(CT) of chest (from neck to upper abdomen) and/or
endoscopic ultrasonography (EUS) were performed for
clinical staging. After intravenous administration of con-
trast, CT of the chest was performed in 5-mm sections.
EUS was carried out with a radial scanning videoechoen-
doscope at 12 MHz (Olympus UM-2R). Some of the
patients did not receive EUS because of the esophageal
stenosis or distant metastases were already detected by
CT of the chest. Bronchoscopy was used to verify tra-
cheoesophageal (T-E) fistula in selected patients. After
CT scan or/and EUS were available, pretreatment clinical
staging was determined according to the 7th American
Joint Committee on Cancer (AJCC) staging system.
Among these 360 patients, there were 33 patients with
AJCC 7th stage I disease, 86 patients with AJCC 7th stage
II disease, 201 patients with AJCC 7th stage III disease,
and 40 patients with AJCC 7th stage IV disease.
Of these 360 esophageal squamous cell carcinoma
patients, 288 patients received bone scan during pre-
treatment staging, and 72 patients did not receive bone
scan during pretreatment staging (Figure 1). Sensitivity,
specificity, positive predictive value, and negative pre-
dictive value of bone scan in patients with esophageal
squamous cell carcinoma were determined according to
the results of these 288 patients.
Of these 360 patients, surgery was performed in 161
patients including 119 patients with preoperative bone
scan and 42 patients without preoperative bone scan.
Among these 161 patients receiving surgery, 133 patients
had stages II + III disease, including 99 patients with pre-
operative bone scan and 34 patients without preoperative
bone scan. All patients undergoing surgery had a radical
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Figure 1 Patient enrollment and study flow diaphragm. CCRT, concurrent chemoradiotherapy; RT, radiotherapy; BSC, best supportive care;
Op, operation; Pre-op CCRT +op, preoperative concurrent chemoradiotherapy followed by operation.
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Lewis esophagectomy with intrathoracic anastomosis,
two-field lymphadenectomy, reconstruction of digestive
tract with gastric tube and pylorus drainage procedures.
Bone recurrence-free survival and overall survival were
compared in all 161 patients and 133 stages II + III
patients, respectively.
Bone scan
99mTc-labelled methylene diphosphonate was used for
whole-body bone scan. Bone scans were interpreted by
an experienced nuclear medicine physician according to
standard clinical practice, using intensity, configuration,
location, and number of foci of abnormal radiotracer ac-
tivity. Bone scan was considered positive for bone me-
tastasis if radiotracer activity in the lesion was greater
than that in normal bone, and the abnormal findings
were multiple and asymmetric. Bone scan was consid-
ered negative for bone metastasis if there was no scinti-
graphic abnormality, or if there was a reasonable
explanation of those scintigraphic findings for benign
causes (osteoarthritis, osteomalacia, traumatic insults),
or equivocal findings. If positive bone scan was noted,
further investigation was performed using X-rays, com-
puted tomography (CT) scans, magnetic resonance im-
aging (MRI) scans, radiologically guided bone biopsy or
a combination of techniques.
Confirmation of bone metastases
Patients were confirmed to have bone metastases if any
of the following criteria were present: positive bonebiopsy or radiographic confirmation by other imaging
modalities such as X-rays, CT scans, and MRI scans. For
patients with equivocal findings during initial radio-
logical examination, further radiological follow-up within
6 months is necessary to confirm bone metastasis. For
patients receiving esophagectomy, the bone metastasis
events were recorded until death or the last follow-up.
Bone recurrence was defined as bone metastasis
detected as the first site of recurrence after esophagect-
omy or detected within 1 month of first site of recur-
rence after esophagectomy [7,13]. For patients who did
not receive esophagectomy, the bone metastasis events
were recorded within 6 months of initial bone scan.
Therefore, a negative bone scan was considered as false
negative if confirmed bone metastasis occurred after
esophagectomy in patients with surgery or within
6 months of initial bone scan in patients without
surgery.
Statistical analysis
Statistical analyses were performed using the SPSS 17
software package. Sensitivity, specificity, positive predict-
ive value, and negative predictive value were calculated
using the classical method. The chi-square test, Fisher’s
exact test, and student t test were employed to compare
data between the two groups. Overall survival (OS) was
calculated from the date of diagnosis to death as a result
of all causes. Bone recurrence-free survival is computed
from the time of surgery to the bone recurrence. To cal-
culate the bone recurrence-free survival, patients who
died without evidence of recurrence or recurrence other
Li et al. BMC Cancer 2012, 12:328 Page 4 of 10
http://www.biomedcentral.com/1471-2407/12/328than bone were censored. The Kaplan–Meier method
was used for univariate survival analysis, and the differ-
ence between survival curves was tested by a log-rank
test. In a stepwise forward fashion, parameters with P
values < 0.05 at univariate level were entered into Cox
regression model to analyze their relative prognostic im-
portance. However, as component factors of 7thAJCC
staging system, 7th T stage and 7th N stage were not
introduced in multivariate analyses. For all analyses,
two-sided tests of significance were used with P < 0.05
considered significant.Results
Sensitivity, specificity, positive predictive value, and
negative predictive value in patients with esophageal
squamous cell carcinoma
Of the 360 esophageal squamous cell carcinoma
patients, whole-body bone scan was performed in 288
patients, and 119 of them received esophagectomy. Of
the 119 patients receiving esophagectomy, 4 patients
developed bone metastasis at 69 days, 104 days, 263 days,
and 638 days respectively after esophagectomy (Figure 1).
Among the 288 patients with whole-body bone scan,
there were 23 patients with AJCC 7th stage I disease, 69
patients with AJCC 7th stage II disease, 165 patients with
AJCC 7th stage III disease, and 31 patients with AJCC
7th stage IV disease (Table 1). Of the 72 patients without
whole-body bone scan staging, 42 patients received eso-
phagectomy, and bone metastasis occurred in 6 patients
at 70 days, 94 days, 226 days, 253 days, 363 days, and
913 days respectively after esophagectomy (Figure 1).
Among 288 patients receiving bone scan, bone scan
was positive in 46 patients and negative in 242 patients.
Positive bone scan was significantly associated with
T3 + 4 disease (P = 0.023, data not shown) and stage IV
disease (P = 0.017, data not shown). Patients with positive
bone scan had significantly (P = 0.006, data not shown)
worse overall survival than those with negative bone
scan. The median overall survivals were 248 days and
434 days in patients with positive and negative bone scan,
respectively. The 3-year overall survival rates were 13%
and 29% in patients with positive and negative bone scan,
respectively.Table 1 Sensitivity, specificity, PPV, and NPV of bone scan in





All (n = 288) 25 46 80.0% (20
Stage I (n = 23) 0 2 -(0/
Stage II (n = 69) 4 10 75.0% (3/
Stage III (n = 165) 13 24 76.9% (10
Stage IV (n = 31) 8 10 87.5% (7/
PPV, positive predictive value; NPV, negative predictive value.Of the 242 patients with negative bone scan, 109
patients received esophagectomy. Of the 109 patients
who received esophagectomy, 3 patients developed bone
recurrence at 69 days, 263 days, and 638 days after eso-
phagectomy. Of the 133 patients who did not receive
esophagectomy, 2 patients developed bone metastasis
within six months of initial negative bone scan
(Figure 1).
Of the 46 patients with positive bone scan, 19 patients
had bone metastases confirmed by X-rays in 1 patient,
CT scans in 6 patients (pelvic CT in 2 patients, brain
CT in one patient, and chest CT in 3 patients), MRI
scans in 6 patients, and positive bone biopsy in 6
patients, respectively. In the remaining 27 patients, 10
patients received esophagectomy, and 1 patient was con-
firmed to have bone metastases 104 days after esopha-
gectomy (Figure 1).
Of the 360 esophageal squamous cell carcinoma
patients, 33 patients were confirmed to have bone me-
tastases eventually and 327 patients were not. (Figure 1)
The median overall survivals of 33 patients with con-
firmed bone metastasis and 327 patients without con-
firmed bone metastasis were 219 days and 419 days,
respectively (P < 0.001, data not shown). The 3-year
overall survival rates of 33 patients with confirmed bone
metastasis and 327 patients without confirmed bone me-
tastasis were 3% and 27%, respectively.
The presence of positive bone scan as an indication of
metastasis presented 80% sensitivity, 90.1% specificity,
43.5% positive predictive value (PPV), and 97.9% nega-
tive predictive value (NPV). (Table 1) Then we per-
formed subgroup analysis according to the 7th AJCC
stage. In 23 patients with stage I esophageal squamous
cell carcinoma of our series, there were no evidence of
bone metastasis. The sensitivity, specificity, PPV, and
NPV of bone scan in patients with stage II, III, and IV
esophageal squamous cell carcinoma are shown in
Table 1.Absence of preoperative bone scan is significantly
associated with inferior bone recurrence-free survival
For patients with resectable esophageal squamous cell
carcinoma, multiple treatment protocols including288 patients with esophageal squamous cell carcinoma
ty Specificity PPV NPV
/25) 90.1% (237/263) 43.5% (20/46) 97.9% (237/242)
0) 91.3% (21/23) 0% (0/2) 100.0% (21/21)
4) 89.2% (58/65) 30.0% (3/10) 98.3% (58/59)
/13) 90.8% (138/152) 41.7% (10/24) 97.9% (138/141)
8) 87.0% (20/23) 70.0% (7/10) 95.2% (20/21)
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chemoradiotherapy (CCRT) followed by esophagectomy
[16,17], or definitive chemoradiotherapy [18,19] is pre-
ferred according to patient selection, physician prefer-
ence, or comorbidity status. Evaluating the role of bone
scan in different treatment protocols is difficult. How-
ever, if bone scan plays an important role in the staging
of esophageal squamous cell carcinoma, it is reasonable
to expect a significant reduction in the number of
patients presenting with bone recurrence after esopha-
gectomy. Therefore, we compared the bone recurrence-
free survival between 119 patients with preoperative
bone scan and 42 patients without preoperative bone
scan. Four of the 119 patients with preoperative
bone scan and 6 of 42 patients without preoperative
bone scan developed bone recurrence. There was no sig-
nificant difference between the two groups in baseline
characteristics including age, sex, treatment protocol
(esophagectomy alone or preoperative CCRT followed
by esophagectomy), T stage, N stage, 7th AJCC stage,
and surgical margin (Table 2). Univariate analysis
(Table 3) showed that lymph node involvement
(P = 0.014), 7th AJCC stages III (P = 0.004), and absence
of preoperative bone scan (P = 0.009, Figure 2A) were
significantly associated with inferior bone recurrence-
free survival after esophagectomy. In multivariate com-
parison, absence of preoperative bone scan (P = 0.012,
odds ratio: 5.053, 95% confidence interval: 1.419-17.986)
and 7th AJCC stage III (P = 0.010, odds ratio: 7.891, 95%
confidence interval: 1.630-38.190) represented the inde-
pendent adverse prognosticator. The 3-year bone
recurrence-free survival rates were 95% and 75% inTable 2 Clinicopathologic features of 119 esophageal squamo
and 42 esophageal squamous cell carcinoma patients withou
Parameters No. of patients
With bone scan before op




Pre-op CCRT + op 52
Primary tumor T1 + 2 41
T3 + 4 78
Lymph node Negative 55
Positive 64
7th AJCC stage I + II 60
III 59
Surgical margin Positive 10
Negative 109
Op, operation; CCRT, concurrent chemoradiotherapy; х2 test, Fisher’s exact test, or tpatients with and without preoperative bone scan,
respectively.
In our series, we did not find bone metastasis in 23
patients with stage I esophageal squamous cell carcin-
oma, indicating that bone scan could be overlooked in
patients with stage I esophageal squamous cell carcin-
oma in the future. Hence, subgroup analysis was per-
formed to investigate the role of bone scan in patients
with 7th AJCC stages II + III esophageal squamous cell
carcinoma. The bone recurrence-free survival between
99 stages II + III patients with preoperative bone scan
and 34 stages II + III patients without preoperative bone
scan were compared. There was no significant difference
between the two groups in baseline characteristics in-
cluding age, sex, treatment protocol (esophagectomy
alone or preoperative CCRT followed by esophagect-
omy), T stage, N stage, 7th AJCC stage, and surgical mar-
gin. (data not shown) By log-rank tests (Table 3), 7th
AJCC stages III (P =0.037) and absence of preoperative
bone scan (P =0.003, Figure 2B) were significantly asso-
ciated with inferior bone recurrence-free survival. Multi-
variate analysis showed that absence of preoperative
bone scan (P = 0.009, odds ratio: 5.832, 95% confidence
interval: 1.509-19.195) was the independent negative fac-
tor of bone recurrence-free survival. The 3-year bone
recurrence-free survival rates were 93% and 60% in
stages II + III patients with and without preoperative
bone scan, respectively.
Later, we evaluate whether superior bone recurrence-
free survival may convert into the overall survival advan-
tage. We compared the overall survival between 119
patients with preoperative bone scan and 42 patientsus cell carcinoma patients with preoperative bone scan
t preoperative bone scan
P value














test was used for statistically analyzed.
Table 3 Results of univariate log-rank analysis of prognostic factors for bone recurrence-free survival in all patients
(n =161) receiving esophagectomy or stage II + III patients (n = 133) receiving esophagectomy
Factors No. of patients
(All, n= 161)
Bone recurrence-free
survival (All, n = 161)
No. of patients
(Stage II + III, n = 133)
Bone recurrence-free
survival (Stage II + III, n = 133)
No. of events P value No. of events P value
Bone scan before op
Absent 42 6 0.009* 34 6 0.003*
Present 119 4 99 4
Sex
Male 156 10 0.480 129 10 0.475
Female 5 0 4 0
Age
<55y/o 88 4 0.417 71 4 0.584
>55y/o 73 6 62 6
Tumor location
Upper/middle 82 4 0.514 66 4 0.555
Lower 79 6 67 6
Protocol
Op 95 5 0.336 69 5 0.715
Pre-op CCRT + op 66 5 64 5
T stage
T1 + 2 53 2 0.160 25 2 0.757
T3 + 4 108 8 108 8
N stage
Negative 75 2 0.014* 47 2 0.100
Positive 86 8 86 8
7thAJCC stage
I + II 80 2 0.004* 52 2 0.037*
III 81 8 81 8
Surgical margin
Positive 12 0 0.505 10 0 0.604
Negative 149 10 123 10
Op, operation; CCRT, concurrent chemoradiotherapy *Statistically significant.
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cant difference in overall survival between 119 patients
with preoperative bone scan and 42 patients without
preoperative bone scan (P = 0.158, Table 4 and
Figure 2C). Univariate analysis (Table 4) showed that
T3 + 4 (P < 0.001), lymph node involvement (P < 0.001),
7th AJCC stages III (P < 0.001), and positive surgical mar-
gin (P = 0.006) were significantly associated inferior over-
all survival. The median overall survivals were 860 days
and 467 days in patients with and without preoperative
bone scan, respectively. The 3-year overall survival rates
were 44% and 31% in patients with and without pre-
operative bone scan, respectively. Then, we compared
the overall survival between 99 stages II + III patients
with preoperative bone scan and 34 stages II + III
patients without preoperative bone scan. Univariateanalysis (Table 4) showed that absence of preoperative
bone scan (P = 0.037, Figure 2D), lymph node involve-
ment (P < 0.001), 7th AJCC stages III (P < 0.001), and
positive surgical margin (P < 0.001) were significantly
associated with inferior overall survival. In multivariate
comparison, absence of preoperative bone scan
(P = 0.029, odds ratio: 1.603, 95% confidence interval:
1.048-2.450), 7th AJCC stage III (P = 0.002, odds ratio:
1.926, 95% confidence interval: 1.262-2.937), and positive
surgical margin (P < 0.001, odds ratio: 3.937, 95% confi-
dence interval: 1.953-7.937) represented the independent
adverse prognosticators for overall survival in 133 stages
II + III patients. The median overall survivals were
658 days and 395 days in stages II + III patients with and
without preoperative bone scan, respectively. The 3-year
overall survival rates were 38% and 21% in stages II + III
A. B.
C. D.
Figure 2 Kaplan–Meier plots to predict bone recurrence-free survival according to the presence or absence of preoperative bone scan
in all 161 patients (A) or 133 AJCC 7th stage II + III patients (B). Kaplan–Meier plots to predict overall survival according to the presence or
absence of preoperative bone scan in all 161 patients (C) or 133 AJCC 7th stage II + III patients (D).
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respectively.
Discussion
Among 288 patients with bone scan during pretreatment
staging in the present study, bone metastasis was con-
firmed in 19 (6.6%) patients. Previous studies[13,20,21]
showed that the incidence of bone metastasis in esopha-
geal cancer during pretreatment staging was 4-9%. In
the present study, 10 (6.2%) of 161 patients receivingesophagectomy developed bone recurrence. In the previ-
ous studies, [6,13,22,23] 5-9% patients developed bone
recurrence after esophagectomy. Our results are similar
to previous studies.
The results of bone scan were negative in 242 patients
(84.0%), and only 5 patients of them developed subse-
quent bone metastases. The negative predictive value
was high, and was not influenced by advanced stage
(stages III and IV). However, the positive predictive
value was low, especially in early-stage patients. Of the
Table 4 Results of univariate log-rank analysis of prognostic factors for overall survival in all patients (n = 161)
receiving esophagectomy or stage II + III patients (n = 133) receiving esophagectomy
Factors No. of patients
(All, n = 161)
Overall survival
(All, n = 161)
No. of patients
(Stage II + III, n = 133)
Overall survival
(Stage II + III, n = 133)
No. of events P value No. of events P value
Bone scan before op
Absent 42 35 0.158 34 32 0.037*
Present 119 79 99 73
Sex
Male 156 113 0.064 129 104 0.075
Female 5 1 4 1
Age
<55y/o 88 63 0.820 71 59 0.161
>55y/o 73 51 62 46
Tumor location
Upper/middle 82 54 0.439 66 48 0.472
Lower 79 60 67 57
Protocol
Op 95 61 0.049* 69 53 0.347
Pre-op CCRT + op 66 53 64 52
T stage
T1 + 2 53 26 <0.001* 25 17 0.113
T3 + 4 108 88 108 88
N stage
Negative 75 39 <0.001* 47 30 <0.001*
Positive 86 75 86 75
7thAJCC stage
I + II 80 43 <0.001* 52 34 <0.001*
III 81 71 81 71
Surgical margin
Positive 12 10 0.006* 10 10 <0.001*
Negative 149 104 123 95
Op, operation; CCRT, concurrent chemoradiotherapy *Statistically significant.
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patients did not have bone metastasis, and in stage II
patients, the positive predictive value was only 30.0%. It
is important, therefore, the interpretation of bone scan
need to take into consideration the context of clinical
symptoms as well as any possible reasonable explanation
for benign causes and the positive findings should be
confirmed by further examinations such as X-rays, CT
scans or MRI scans.
In our study, we did not find bone metastasis in 23
patients with stage I esophageal squamous cell carcin-
oma with a median follow-up of 1442 days, indicating
that bone scan could be omitted in patients with stage I
esophageal squamous cell carcinoma. Bhansali et al. [7]
also described that no recurrence occurred from
15 esophageal squamous cell carcinoma patients withpT1 tumor. However, Mariette et al. [24] reported that
for pT1 esophageal cancer, no recurrence occurred in
12 patients with tumor restricted to mucosa whereas re-
currence was observed in 25 (31.8%) patients with tumor
restricted to submucosa. But, the study from Mariette,
et al. [24] included both esophageal squamous cell car-
cinoma and adenocarcinoma, and they described that
distant recurrences occurred more frequently with
adenocarcinoma. Therefore, we suggest that bone scan
may be unnecessary for esophageal squamous cell car-
cinoma restricted to mucosa. For esophageal squamous
cell carcinoma restricted to submucosa, further study is
needed.
As previously described, there have been doubts about
the routine use of bone scan in esophageal cancer. Fur-
thermore, the majority of histology type in previous
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adenocarcinoma, not esophageal squamous cell carcin-
oma. Large series data regarding the value of routine
bone scan in esophageal squamous cell carcinoma are
scant. Multiple treatment choices including surgery
alone, preoperative CCRT followed by surgery, definite
chemoradiotherapy, radiotherapy alone can be applied to
patients with resectable esophageal squamous cell car-
cinoma according to patient selection, physician prefer-
ence, or comorbidity status. Such hampered our
evaluation on the role of bone scan in esophageal sqau-
mous cell carcinoma. However, if bone scan has an ap-
preciable role in the initial staging of esophageal
squamous cell carcinoma, it is logical to expect signifi-
cantly superior bone recurrence-free survival in patients
receiving esophagectomy. Indeed, in our univariate ana-
lysis, absence of preoperative bone scan correlated with
inferior bone recurrence-free survival, and it remained
prognostically independent in multivariate comparison,
suggesting that bone scan should be routinely performed
before esophagectomy in patients with esophageal squa-
mous cell carcinoma. Additionally, we found that lymph
node involvement was associated with inferior bone
recurrence-free survival. Previous studies [7,24] also
showed the correlation between lymph node involve-
ment and distant organ recurrence. Our results further
support previous findings.
In our series, bone metastasis was not detected in
23 stage I patients, indicating that bone scan could be
omitted in stage I patients in the future. Hence, we
perform subgroup analysis to evaluate the role of bone
scan in stages II + III patients. In our univariate and
multivariate analysis, absence of preoperative bone
scan was significantly associated with inferior bone
recurrence-free survival in stages II + III patients. We
also found that absence of preoperative bone scan sig-
nificantly correlated with inferior overall survival in
stages II + III patients. It suggests that preoperative
bone scan is a valuable tool in patients with esopha-
geal squamous cell carcinoma, especially in patients
with advanced stages.
Our study has important limitations. First, our results
are based on the retrospective analysis. The retrospective
design of this analysis further justifies the conclusion
that a prospective study in the future is needed to define
our findings. Second, most of the patients in this study
did not have fluorodeoxyglucose positron emission tom-
ography (FDG-PET) as comparison because it is not
routinely supported by Taiwan’s health-insurance system.
Third, the patients in the present study were staged
based on the CT of the chest or/and EUS. The bone
scan findings were not integrated into staging. There-
fore, the disease staging in the preset study may be
understaged.Conclusions
In conclusion, our study revealed that absence of pre-
operative bone scan is significantly associated with infer-
ior bone recurrence-free survival. Therefore, we suggest
that whole-body bone scan should be performed before
esophagectomy in patients with esophageal squamous
cell carcinoma, especially in patients with advanced
stages.
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